Turq-101
Inflammatory Bowel Disease
PreclinicalActive
Key Facts
About Turquoise Biotechnologies
Exosome‑engineered delivery platform for targeted therapeutics across oncology and autoimmune diseases.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| GS-4875 | Gilead | Phase 2 |
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |
| Noa‑001 | Noa Therapeutics | Preclinical |
| Inflectra | EMS | Phase 3 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| TRWR‑IBD | Taiwan Resonant Waves Research | Preclinical |
| Zymfentra™ | Celltrion | Marketed |
| IBD98-M | Holy Stone Healthcare | Preclinical |